Literature DB >> 19952304

Three-dimensional overlay culture models of human breast cancer reveal a critical sensitivity to mitogen-activated protein kinase kinase inhibitors.

Quanwen Li1, Albert B Chow, Raymond R Mattingly.   

Abstract

Tumor cells that are grown in three-dimensional (3D) cell culture exhibit relative resistance to cytotoxic drugs compared with their response in conventional two-dimensional (2D) culture. We studied the effects of targeted agents and doxorubicin on 2D and 3D cultures of human breast cell lines that represent the progression from normal epithelia (modeled by MCF10A cells) through hyperplastic variants to a dysplastic/carcinoma phenotype (MCF10.DCIS cells), variants transformed by expression of activated Ras, and also a basal-subtype breast carcinoma cell line (MDA-MB-231). The results showed the expected relative resistance to the cytotoxic agent doxorubicin in 3D cultures, with greater resistance in normal and hyperplastic cells than in carcinoma models. However, the response to the targeted inhibitors was more complex. Inhibition of mitogen-activated protein kinase kinase (MEK) by either 1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) or 2-(2-chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide (CI-1040, PD184352) produced a similar inhibition of the growth of all the MCF10 cell lines in 2D. In 3D culture, the normal and hyperplastic models exhibited some resistance, whereas the carcinoma models became far more sensitive to MEK inhibition. Increased sensitivity to MEK inhibition was also seen in MDA-MB-231 cells grown in 3D compared with 2D. In contrast, inhibition of phosphatidylinositol 3'-kinase activity by wortmannin had no significant effect on the growth of any of the cells in either 2D or 3D. Our conclusion is that 3D culture models may not only model the relative resistance of tumor cells to cytotoxic therapy but also that the 3D approach may better identify the driving oncogenic pathways and critical targeted inhibitors that may be effective treatment approaches.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19952304      PMCID: PMC2835447          DOI: 10.1124/jpet.109.160390

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  30 in total

Review 1.  Modeling tissue-specific signaling and organ function in three dimensions.

Authors:  Karen L Schmeichel; Mina J Bissell
Journal:  J Cell Sci       Date:  2003-06-15       Impact factor: 5.285

2.  Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures.

Authors:  Jayanta Debnath; Senthil K Muthuswamy; Joan S Brugge
Journal:  Methods       Date:  2003-07       Impact factor: 3.608

3.  Down-regulation of growth factor-stimulated MAP kinase signaling in cytotoxic drug-resistant human neuroblastoma cells.

Authors:  R R Mattingly; M L Milstein; B L Mirkin
Journal:  Cell Signal       Date:  2001-07       Impact factor: 4.315

Review 4.  Multicellular resistance: a paradigm for clinical resistance?

Authors:  B Desoize; J Jardillier
Journal:  Crit Rev Oncol Hematol       Date:  2000 Nov-Dec       Impact factor: 6.312

5.  Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology.

Authors:  F Wang; V M Weaver; O W Petersen; C A Larabell; S Dedhar; P Briand; R Lupu; M J Bissell
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

6.  Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis.

Authors:  Lynn B Eckert; Gretchen A Repasky; Aylin S Ulkü; Aidan McFall; Hong Zhou; Carolyn I Sartor; Channing J Der
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

7.  Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts.

Authors:  Fei Wang; Rhonda K Hansen; Derek Radisky; Toshiyuki Yoneda; Mary Helen Barcellos-Hoff; Ole W Petersen; Eva A Turley; Mina J Bissell
Journal:  J Natl Cancer Inst       Date:  2002-10-02       Impact factor: 13.506

8.  Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells.

Authors:  B S Croix; J W Rak; S Kapitain; C Sheehan; C H Graham; R S Kerbel
Journal:  J Natl Cancer Inst       Date:  1996-09-18       Impact factor: 13.506

Review 9.  CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).

Authors:  Lee F Allen; Judith Sebolt-Leopold; Mark B Meyer
Journal:  Semin Oncol       Date:  2003-10       Impact factor: 4.929

10.  Identification of a novel inhibitor of mitogen-activated protein kinase kinase.

Authors:  M F Favata; K Y Horiuchi; E J Manos; A J Daulerio; D A Stradley; W S Feeser; D E Van Dyk; W J Pitts; R A Earl; F Hobbs; R A Copeland; R L Magolda; P A Scherle; J M Trzaskos
Journal:  J Biol Chem       Date:  1998-07-17       Impact factor: 5.157

View more
  43 in total

1.  Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.

Authors:  Thomas D Wright; Christopher Raybuck; Akshita Bhatt; Darlene Monlish; Suravi Chakrabarty; Katy Wendekier; Nathan Gartland; Mohit Gupta; Matthew E Burow; Patrick T Flaherty; Jane E Cavanaugh
Journal:  J Cell Biochem       Date:  2019-08-28       Impact factor: 4.429

2.  3D/4D functional imaging of tumor-associated proteolysis: impact of microenvironment.

Authors:  Kamiar Moin; Mansoureh Sameni; Bernadette C Victor; Jennifer M Rothberg; Raymond R Mattingly; Bonnie F Sloane
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

Review 3.  Spatio-temporal modeling and live-cell imaging of proteolysis in the 4D microenvironment of breast cancer.

Authors:  Kyungmin Ji; Mansoureh Sameni; Kingsley Osuala; Kamiar Moin; Raymond R Mattingly; Bonnie F Sloane
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

4.  Spheroid assay to measure TGF-β-induced invasion.

Authors:  Hildegonda P H Naber; Eliza Wiercinska; Peter Ten Dijke; Theo van Laar
Journal:  J Vis Exp       Date:  2011-11-16       Impact factor: 1.355

Review 5.  Microscale screening systems for 3D cellular microenvironments: platforms, advances, and challenges.

Authors:  Sara I Montanez-Sauri; David J Beebe; Kyung Eun Sung
Journal:  Cell Mol Life Sci       Date:  2014-10-02       Impact factor: 9.261

6.  Three dimensional cultures: a tool to study normal acinar architecture vs. malignant transformation of breast cells.

Authors:  Anupama Pal; Celina G Kleer
Journal:  J Vis Exp       Date:  2014-04-25       Impact factor: 1.355

Review 7.  In Vitro Models for Studying Invasive Transitions of Ductal Carcinoma In Situ.

Authors:  Ethan J Brock; Kyungmin Ji; Seema Shah; Raymond R Mattingly; Bonnie F Sloane
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-07-28       Impact factor: 2.673

Review 8.  Using polymeric materials to control stem cell behavior for tissue regeneration.

Authors:  Nianli Zhang; David H Kohn
Journal:  Birth Defects Res C Embryo Today       Date:  2012-03

9.  MicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition.

Authors:  Jon S Zawistowski; Kazuhiro Nakamura; Joel S Parker; Deborah A Granger; Brian T Golitz; Gary L Johnson
Journal:  Mol Cell Biol       Date:  2013-03-25       Impact factor: 4.272

Review 10.  Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ.

Authors:  Hitchintan Kaur; Shihong Mao; Seema Shah; David H Gorski; Stephen A Krawetz; Bonnie F Sloane; Raymond R Mattingly
Journal:  Expert Rev Mol Diagn       Date:  2013-03       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.